Danaher Corporation · NYSE:DHR
Danaher — J.P. Morgan Healthcare Conference 2021
8 slides from Danaher's conference presentation, Jan 13, 2021
Slide 1: Forward Looking Statements
2 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding Danaher’s anticipated financial performance for the fourth quarter 2020 or any other period, and any other statements regarding events or developments that we anticipate
Slide 2: Non-GAAP Reconciliations
3 Non-GAAP Reconciliations Estimated Core Sales Growth, Core Sales Growth Including Cytiva and Base Business Core Sales Growth % Change Three-Month Period Ended December 31, 2020 vs. Comparable 2019 Period % Change Year Ended December 31, 2020 vs. Comparable 2019 Period Total sales growth (GAAP) ~38
Slide 3: Current Update: Strong finish to 2020
Current Update 5 Strong finish to 2020 Q4 RESULTS BETTER THAN OUR EXPECTATIONS Q4 ESTIMATED CORE REVENUE GROWTH INCL. CYTIVA UP ~15% — Led by Life Sciences and Diagnostics; EAS up slightly — COVID-related tailwinds contributed ~1,100-1,200bps to core growth — “Base” business +LSD/MSD (despite 3 fewe
Slide 4: Danaher Today
Danaher Today Purpose-driven science & technology leader ~$22B 2020E DANAHER TOTAL REVENUE 6 LIFE SCIENCES $10.6B DIAGNOSTICS $7.4B ENV. & APPLIED $4.3B All financial metrics reflect estimated FY 2020E results from continuing operations Pie chart is a % of total revenue and includes Cytiva 2020E tot
Slide 5: Building a stronger, better Danaher
Building a stronger, better Danaher 2015 2018 2020E TOTAL REVENUE ~$21B ~$20B ~$22B CORE REVENUE GROWTH +LSD +MSD +HSD* RECURRING REVENUE ~45% ~70% ~75% ADJUSTED GROSS MARGIN 53% 56% ~58%** OPERATING CASH FLOW $3.8B $4.0B ~$6.0B KEY PORTFOLIO MOVES 7 2015 metrics shown include Fortive and Envista; 2
Slide 6: GE Biopharma Acquisition (Cytiva)
GE Biopharma Acquisition (Cytiva) 8 Transformational addition to our Life Sciences platform GLOBAL LEADER IN FAST-GROWING, HIGHLY- ATTRACTIVE BIOPROCESSING MARKET • Closed the transaction March 2020 • Talented & innovative team with industry-leading expertise • Transition update: ― Re-branding to ne
Slide 7: Bioprocessing: Where We Play & How We Win
Bioprocessing: Where We Play & How We Win 9 Filtration Skids & Consumables Concentration & Sterile Filtration Media Bioreactor Depth Filter Chromatography Columns Polishing Column Devices Bags & Mixers Helping customers bring more life-saving drugs to market faster Cell culture & SUT Chromatography
Slide 8: Molecular Diagnostics: Where We Play & How We Win
Molecular Diagnostics: Where We Play & How We Win 10 HOW WE WIN • Largest global installed base: ~30,000 instruments • Broadest test menu: >35 OUS, >20 in the US • Workflow + speed + accuracy Unique & leading position in critical point-of-care environments Cepheid GeneXpert® Systems & test cartridge